Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025
Y-mAbs Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 62.29 | 67.23 | 78.64 | 105.76 | 181.56 | 114.63 |
Cash & Short-Term Investments | 62.29 | 67.23 | 78.64 | 105.76 | 181.56 | 114.63 |
Cash Growth | -19.94% | -14.50% | -25.65% | -41.75% | 58.39% | -44.66% |
Receivables | 15.74 | 19.69 | 22.45 | 12.53 | 7.71 | - |
Inventory | 9.72 | 7.21 | 5.07 | 6.7 | 5.51 | - |
Other Current Assets | 4.04 | 4.37 | 4.96 | 5.45 | 7.47 | 7.73 |
Total Current Assets | 91.79 | 98.51 | 111.11 | 130.45 | 202.26 | 122.36 |
Property, Plant & Equipment | 3.38 | 0.86 | 1.64 | 2.34 | 5.69 | 6.39 |
Other Intangible Assets | 2.18 | 2.28 | 2.63 | 2.99 | 1.66 | - |
Other Long-Term Assets | 19.87 | 18.26 | 12.49 | 5.68 | 3.17 | 3.29 |
Total Assets | 117.21 | 119.9 | 127.87 | 141.46 | 212.78 | 132.05 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 7.57 | 6.66 | 6.06 | 14.18 | 13.55 | 9.37 |
Accrued Expenses | 8.47 | 8.18 | 7.41 | 6.77 | 6.84 | 4.59 |
Current Portion of Leases | 0.49 | 0.63 | 0.9 | 0.87 | 1.78 | 1.97 |
Other Current Liabilities | 6.42 | 8.22 | 5.76 | 6.48 | 5.71 | 3.61 |
Total Current Liabilities | 22.95 | 23.7 | 20.13 | 28.28 | 27.88 | 19.54 |
Long-Term Leases | 2.64 | 0.19 | 0.52 | 0.9 | 1.85 | 2.01 |
Other Long-Term Liabilities | 4.14 | 4.01 | 6.24 | 3.05 | 2.95 | 4.66 |
Total Liabilities | 29.72 | 27.9 | 26.88 | 32.24 | 32.68 | 26.21 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.01 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 583.67 | 576.87 | 558 | 543.93 | 519.21 | 391.56 |
Retained Earnings | -495.57 | -487.14 | -457.47 | -436.04 | -340.48 | -285.2 |
Comprehensive Income & Other | -0.61 | 2.26 | 0.45 | 1.33 | 1.37 | -0.53 |
Shareholders' Equity | 87.49 | 92 | 100.99 | 109.22 | 180.11 | 105.84 |
Total Liabilities & Equity | 117.21 | 119.9 | 127.87 | 141.46 | 212.78 | 132.05 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 3.12 | 0.82 | 1.42 | 1.77 | 3.63 | 3.98 |
Net Cash (Debt) | 59.17 | 66.41 | 77.22 | 104 | 177.93 | 110.66 |
Net Cash Growth | -22.69% | -13.99% | -25.75% | -41.55% | 60.80% | -46.00% |
Net Cash Per Share | 1.32 | 1.50 | 1.77 | 2.38 | 4.12 | 2.76 |
Filing Date Shares Outstanding | 45.44 | 45.22 | 43.78 | 43.68 | 43.71 | 43.53 |
Total Common Shares Outstanding | 45.44 | 44.99 | 43.67 | 43.67 | 43.69 | 40.69 |
Working Capital | 68.84 | 74.81 | 90.98 | 102.16 | 174.39 | 102.83 |
Book Value Per Share | 1.93 | 2.05 | 2.31 | 2.50 | 4.12 | 2.60 |
Tangible Book Value | 85.32 | 89.73 | 98.35 | 106.24 | 178.44 | 105.84 |
Tangible Book Value Per Share | 1.88 | 1.99 | 2.25 | 2.43 | 4.08 | 2.60 |